- Previous Close
0.0495 - Open
0.0500 - Bid --
- Ask --
- Day's Range
0.0490 - 0.1374 - 52 Week Range
0.0490 - 0.1374 - Volume
787,484 - Avg. Volume
-- - Market Cap (intraday)
-- - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Abpro Holdings, Inc., a biotechnology company, engages in developing antibody therapeutics for patients with immuno-oncology, ophthalmology, and autoimmunity issues. Its platform DiversImmune addresses a bottleneck in the antibody therapeutics industry. Its lead product candidates include ABP-100 for the treatment of breast, gastric, and colorectal cancers; and ABP-201 for the treatment of vascular diseases of the eye. The company has a strategic partnership with Abpro Bio Co. Ltd and NJCTTQ. The company was formerly known as Abpro Corporation and changed its name to Abpro Holdings, Inc. in November 2024. Abpro Holdings, Inc. was incorporated in 2004 and is headquartered in Woburn, Massachusetts.
abpro.comRecent News: ABPWW
View MoreCompare To: ABPWW
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ABPWW
View MoreValuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
72k
Net Income Avi to Common (ttm)
-8.09M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
63k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--